DOCSLIB.ORG

VACCINES and DIALYSIS What You Need to Know

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
VACCINES and DIALYSIS What You Need to Know VACCINES AND DIALYSIS What You Need to Know www.kidney.org COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries that help your healthcare provider make decisions about your medical treatment? The information in this booklet is based on those recommended guidelines. Stages of Kidney Disease There are five stages of kidney disease. They are shown in the table below. Your healthcare provider determines your stage of kidney disease, based on the presence of kidney damage and your glomerular filtration rate (GFR), which is a measure of your kidney function. Your treatment is based on your stage of kidney disease. Speak to your healthcare provider if you have any questions about your stage of kidney disease or your treatment. STAGES OF KIDNEY DISEASE Stage Description Glomerular Filtration Rate (GFR)* Kidney damage (e.g., protein 1 90 or above in the urine) with normal GFR Kidney damage with mild 2 60 to 89 decrease in GFR 3 Moderate decrease in GFR 30 to 59 4 Severe reduction in GFR 15 to 29 5 Kidney failure Less than 15 *Your GFR number tells your healthcare provider how much kidney function you have. As chronic kidney disease progresses, your GFR number decreases. 2 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. TABLE OF CONTENTS Why do I need vaccines? .................. 4 Do I need vaccines if I am on dialysis? ........5 How do vaccines work?. .5 Are vaccines safe? ........................5 Which vaccines do I need and when do I need them?. .................7 What if I have more questions? .............13 WWW.KIDNEY.ORG 3 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Vaccines protect you from serious diseases, so they are an important part of your healthcare. This educational brochure will help answer some questions you may have about vaccines for people on dialysis. Why do I need vaccines? Vaccines help protect people from diseases caused by infections from certain germs (viruses or bacteria). Some common diseases are the flu (or influenza), hepatitis B, tetanus, pneumococcus, and others. Many of these diseases can make you very sick and cause death. People with these diseases can pass them along and make others around them sick, so vaccines can also help protect others. Certain people have a higher chance of being seriously ill from these diseases, so they especially need protection. They include the elderly, children, and people with chronic illnesses including those on dialysis. 4 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Do I need vaccines if I am on dialysis? Yes. Your body’s immune system helps protect you from infections. However, people on dialysis can have weaker immune systems, making it harder to fight off infections. People on dialysis have a greater chance of getting an infection. There is also a greater chance of that infection becoming serious. Therefore, vaccines are an important part of healthcare for people on dialysis. How do vaccines work? Vaccines are usually given as a “shot” (an injection with a small needle). They protect you by helping your body’s immune system “prepare” for a real infection. To do this, vaccines contain parts of a dead or weakened germ. Once you get the shot, your body produces antibodies, which help your body find and kill these germs. Should you come in contact with the real germ, these antibodies will work to protect you. Some vaccines need a booster shot to help your body’s immune system make enough antibodies. This is why some vaccines might need one shot, while others need more than one shot. In some cases, a blood test is used to make sure there are enough antibodies for protection. Are vaccines safe? Vaccines are among the safest therapies available. They have protected millions of people from serious diseases. As with any medicine, there are some possible side effects. Some people could feel minor discomfort. There could be some soreness or a mild rash on the skin where the shot was given. Others might get a slight fever. However, these mild effects are normal and should not cause alarm. WWW.KIDNEY.ORG 5 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. There are some people who should not receive vaccines, including those allergic to vaccines, or people with an overactive immune system. Also, women who are pregnant, people with a kidney transplant, or those with a less active immune system should not receive certain vaccines. Some people are concerned that vaccines might cause autism. However, multiple studies show that there is no connection between receiving vaccines and getting autism. The possible harm from vaccines is very small. The possible harm from infection is much greater. As with any medicine, talk with a healthcare provider about any questions or concerns you have about vaccines. 6 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Which vaccinations do I need and when do I need them? Vaccines that are recommended for people on dialysis include flu (or influenza), hepatitis B, pneumococcus, Tdap (tetanus/diphtheria/pertussis), and others. You might need one shot to protect you for life. Other vaccines might need more than one shot to build up enough protection. Flu The flu (or influenza) vaccine is commonly called the “flu shot.” It needs to be given once per year, usually in the fall before flu season begins. The flu shot helps prevent infection from the influenza virus. Flu symptoms can include headaches, body aches, high fever, sore throat, fatigue, and a runny nose. The flu can be passed along by casual, person-to- person contact. A flu infection can be very serious for people with a weaker immune system. People on dialysis have a greater chance of getting the flu, so yearly vaccination is very important. Hepatitis B The hepatitis B vaccine helps protect against an infection from the hepatitis B virus (also known as HBV, or hep B). The hepatitis B virus attacks the liver. Symptoms of hepatitis B can include loss of appetite, nausea or vomiting, fever, extreme tiredness, or stomach or joint pain. Some of these symptoms are similar to the flu. However, hepatitis B can also cause a yellowing of the skin or eyes. A blood test can help prove if you have hepatitis B. A hepatitis B infection can cause liver failure or liver cancer. Some people (known as “carriers”) with hepatitis B have no symptoms, but are still able to infect others. Hepatitis B cannot spread by casual, person-to-person WWW.KIDNEY.ORG 7 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. contact, so it cannot be passed along by hugging or shaking hands. It is passed along by direct contact with the blood of an infected person. The chance of getting hepatitis B through dialysis treatment is low because of strict infection control measures in dialysis units, and the availability of the hepatitis B vaccine. However, people on dialysis should still get vaccinated. People are usually given 3 shots to develop protection against HBV. However, people on dialysis might need more shots or a higher dose to develop enough protection. Talk to your healthcare provider about timing and dosage. Pneumococcus The pneumococcal vaccine helps protect against infection from pneumococcal bacteria. There are two types of pneumococcal vaccines: PPSV23 and PCV13. People on dialysis should receive both vaccines. Pneumococcal bacteria can infect many parts of the body. If it infects the lungs, it causes pneumonia. If it enters the bloodstream, it can cause sepsis, leading to poor blood flow and organ damage. Pneumococcal bacteria can infect the covering of the heart. It can also attack the nervous system and cause meningitis. These infections are very serious and can cause death. Because different parts of the body can be infected, symptoms can vary from person to person, and can appear very suddenly and without warning. Depending if the infection causes pneumonia, sepsis, or meningitis, people can feel some combination of these symptoms—fever, shaking/chills, cough, shortness of breath, chest pain, stiff neck, or disorientation. 8 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Some people have a greater chance of getting a pneumococcal infection, including the very young and people 65 years and older. People on dialysis also have a higher chance. Depending on the vaccine and the person, 1 or 2 shots might be needed, followed by a booster shot in 5 years. Ask your healthcare provider about timing and spacing. WWW.KIDNEY.ORG 9 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Tdap (Tetanus, Diphtheria, Pertussis) The Tdap vaccine can protect against infections from three different kinds of germs (bacteria)—tetanus, diphtheria, and pertussis. Diphtheria and pertussis are passed along by casual, person-to-person contact. People can get tetanus from cuts, scrapes, punctures, or other wounds. Diphtheria is rare in the United States, but it can be a serious infection of the nose and throat. Symptoms can include fever, sore throat, weakness, or swollen glands. A telltale sign of diphtheria is a thick coating in the back of the throat, which makes it very difficult to breathe. Diphtheria can also lead to paralysis or heart failure. 10 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Pertussis is also known as whooping cough. Symptoms can include congestion, runny nose, fever, watery eyes, and cough. Pertussis can cause coughing spells that make it hard to breathe or sleep. It can also lead to vomiting and weight loss. A person with pertussis may need to be in the hospital. Tetanus, also known as lockjaw, is rare in the United States today.
Load more

Recommended publications
  • 362.Full.Pdf
    AMERICAN ACADEMY OF PEDIATRICS Committee on Infectious Diseases Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis ABSTRACT. Heptavalent pneumococcal conjugate vac- lular pertussis; HbOC, Haemophilus influenzae type b conjugate cine (PCV7) is recommended for universal use in chil- vaccine; HIV, human immunodeficiency virus; AOM, acute otitis dren 23 months and younger, to be given concurrently media. with other recommended childhood vaccines at 2, 4, 6, and 12 to 15 months of age. For children 7 to 23 months he purpose of this report is to provide recom- old who have not received previous doses of PCV7, ad- ministration of a reduced number of doses is recom- mendations for use of the heptavalent pneumo- mended. Two doses of PCV7 are recommended for chil- Tcoccal conjugate vaccine (PCV7), Prevnar (Led- dren 24 to 59 months old at high risk of invasive erle Laboratories, Pearl River, NY; Wyeth-Ayerst pneumococcal infection—including children with func- Pharmaceuticals, Marietta, PA), and 23-valent pneumo- tional, anatomic, or congenital asplenia; infection with coccal polysaccharide (23PS) vaccines. In addition, rec- human immunodeficiency virus; and other predisposing ommendations for the continuing use of antibiotic pro- conditions—who have not been immunized previously phylaxis in children with sickle cell disease (SCD) and with PCV7. Recommendations have been made for use of asplenia will be given, and the use of antibiotics and 23-valent pneumococcal polysaccharide (23PS) vaccine in vaccines in children who attend out-of-home care will high-risk children to expand serotype coverage.
    [Show full text]
  • Pneumococcal Vaccine Timing for Adults Make Sure Your Patients Are up to Date with Pneumococcal Vaccination
    Pneumococcal Vaccine Timing for Adults Make sure your patients are up to date with pneumococcal vaccination. When both are If either vaccine is PCV13 and PPSV23 Two pneumococcal vaccines are recommended for adults: indicated, PCV13 inadvertently given should not be 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar13®) should be given earlier than the administered during the ® before PPSV23 recommended window, 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23) same office visit. whenever possible. do not repeat the dose. One dose of PCV13 is recommended for adults: One dose of PPSV23 is recommended for adults: 19 years or older with certain medical conditions and who have not 65 years or older, regardless of previous history of vaccination with previously received PCV13. See Table 1 for specific guidance. pneumococcal vaccines. Adults 65 years or older can discuss and decide, with their clinician, – Once a dose of PPSV23 is given at age 65 years or older, no to receive PCV13 if they have not previously received a dose (shared additional doses of PPSV23 should be administered. clinical decision-making). 19 through 64 years with certain medical conditions. – A second dose may be indicated depending on the medical condition. See Table 1 for specific guidance. Adults 65 years or older without an immunocompromising condition, CSF* leak, or cochlear implant For those who have not received any pneumococcal For those who have previously received 1 dose of vaccines, or those with unknown vaccination history PPSV23 at ≥ 65 years and no doses of PCV13 If patient and provider decide PCV13 is not to be given: If patient and provider decide PCV13 is not to be given: Administer 1 dose of PPSV23.
    [Show full text]
  • Adults with DIABETES Are Among Those Who Need Pneumococcal
    Patients with diabetes are at an increased risk for complications from pneumococcal disease. Diabetes may be a unique risk factor for increased incidence of sepsis associated with pneumococcal infection. One of the reasons people with diabetes are at greater risk for pneumococcal disease is that they may have abnormalities in immune function that affect their reaction to infection. Pneumococcal disease causes serious illnesses like pneumonia, meningitis, and sepsis. Pneumococcal disease is serious and deadly. In the US, pneumococcal pneumonia, meningitis, and sepsis kill tens of thousands each year. Pneumococcal disease survivors may suffer hearing loss, seizures, blindness, or paralysis. Pneumococcal vaccination is recommended for all adults with diabetes. Adults with DIABETES Are Among Those Who Need Pneumococcal Vaccination There are two types of pneumococcal vaccine recommended for US adults: a pneumococcal conjugate vaccine (PCV13) and a pneumococcal polysaccharide vaccine (PPSV23). Adults 65 and older, and adults age 19 to 64 years with any of the following need to receive both vaccines: immunocompromising conditions or treatments (e.g., HIV/AIDS, leukemia, lymphoma, Hodgkin disease, radiation therapy); a damaged or missing spleen; cochlear implants; or cerebrospinal fluid leaks. Other adults for whom pneumococcal vaccination is recommended only need PPSV23, but may need more than one dose and will need PCV13 when they, too, reach age 65. Please refer to the Adult Pneumococcal Vaccination Guide or visit cdc.gov/vaccines/vpd-vac/pneumo/ for details on timing of vaccine doses. For more information and resources to educate patients about pneumococcal disease, visit adultvaccination.org/professional-resources/pneumo This initiative is supported by unrestricted educational grants from Merck & Co., Inc.
    [Show full text]
  • 2021 Medicare Vaccine Coverage Part B Vs Part D
    CDPHP® Medicare Advantage Vaccine Coverage Guide Part B (Medical) vs. Part D (Pharmacy) Medicare Part B (Medical): Medicare Part D (Pharmacy): Vaccinations or inoculations Vaccinations or inoculations are included when the administration is (except influenza, pneumococcal, reasonable and necessary for the prevention of illness. and hepatitis B for members at risk) are excluded unless they are directly related to the treatment of an injury or direct exposure to a disease or condition. • Influenza Vaccine (Flu) • BCG Vaccine • Pneumococcal Vaccine • Diphtheria/Tetanus/Acellular Pertussis Vaccine (ADACEL, (Pneumovax, Prevnar 13) BOOSTRIX, DAPTACEL, INFANRIX) • Hepatitis B Vaccine • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus (Recombivax, Engerix-B) Vaccine (KINRIX, QUADRACEL) for members at moderate • Diphtheria/Tetanus Vaccine (DT, Td, TDVAX, TENIVAC) to high risk • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus Vac­ • Other vaccines when directly cine/ Haemophilus Influenzae Type B Conjugate Vaccine (PENTACEL) related to the treatment of an • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus injury or direct exposure to a Vaccine/Hepatitis B Vaccine (PEDIARIX) disease or condition, such as: • Haemophilus Influenzae Type B Conjugate Vaccine (ActHIB, PedvaxHIB, • Antivenom Sera Hiberix) • Diphtheria/Tetanus Vaccine • Hepatitis A Vaccine, Inactivated (VAQTA) (DT, Td, TDVAX, TENIVAC) • Hepatitis B Vaccine, Recombinant (ENGERIX-B, RECOMBIVAX HB) • Rabies Virus Vaccine for members at low risk (RabAvert,
    [Show full text]
  • Global Immunization News 25 February 2011
    Global Immunization News 25 February 2011 World Health Organization Global Immunization News Inside this issue: Technical Information Meeting of the Global Advisory 2 Committee on Vaccine Safety Polio eradication mourns loss of 2 NEW VACCINES, NEW true polio champion OPPORTUNITIES Announcements from The SIVAC 3 25/02/2011 from Hayatee Hasan, WHO/HQ Initiative In the past two months, four countries ― WHO position on pandemic influ- 3 Guyana, Kenya, Sierra Leone and Yemen ― enza vaccination following reports of narcolepsy subsequent to use of have introduced the pneumococcal conjugate Pandemrix vaccine. They represent the first of a series of countries introducing the vaccine in 2011. PHOTO Cold Chain and Logistics Taskforce 3 WHO concludes that quality issues 4 These introductions represent a major relating to Quinvaxem production milestone - the gap between access to new have been resolved vaccines between developed and developing AFRICA 4-6 countries is shortening; it is extraordinary to The launching of the Pneumococcal see a new vaccine launched in a developing conjugate vaccine (PCV-13) in Si- erra Leone country within one to two years of its introduction in the Americas and Europe, Kenya launches ten-valent pneumo- while in the past, it has taken several years coccal conjugate vaccine (PCV10) Vaccine carrier containing pneumococcal vaccine in (averaging 15 years) between the Kenya Meetings held in afro central introduction of new vaccines in developed and developing countries. AMERICAS 6-8 Peru introduces nationwide HPV vaccination; Argentina announces For more information regarding the launches in these countries, please see the articles on HPV vaccine introduction Kenya, Sierra Leone and Yemen.
    [Show full text]
  • Vaccines-Pneumococcal- Influenza- Shingles Q and A
    www.RxFiles.ca - July 2019 RxFiles Q&A Summary A Crawley BSP; J Bareham BSP VACCINES: Pneumococcal, Influenza, & Shingles Immunization Guidelines and Saskatchewan Health Coverage Considerations Vaccines prevent morbidity and mortality to various degrees. Many vaccines are publicly funded, especially if potentially life-saving. When guideline recommendations & public coverage differ, clinicians/patients must weigh the evidence for benefit versus the out-of-pocket patient cost. Note: vaccine costs listed in this document do not include markup, dispensing fees, or administration fees, which can vary depending on who is administering the vaccine. 1. Who may benefit from a PNEUMOCOCCAL vaccine in Saskatchewan? Available vaccines include the PNEUMOVAX 23-valent vaccine ($24) and the PREVNAR 13-valent vaccine ($103). Covered in Sask:1 Evidence for benefit Clinical Controversies 1 dose of PNEUMOVAX for anyone A single pneumococcal vaccination Immunization guidelinesNACI suggest that if ≥65 years old. appears to reduce the risk of PNEUMOVAX was given before the age of 65, a booster 1 dose of PNEUMOVAX for anyone community-acquired pneumonia by dose should be given 5 years later to all patients with specific medical conditions 30% (NNT = 55) and the risk of a COPD regardless of risk factors.18 This recommendation is (e.g. diabetes, COPD, others*). exacerbation by 40% (NNT = 8).2,19,20 based on the tendency for older adults to have a 2 doses of PNEUMOVAX spaced 5+ Benefits are consistent regardless of weakened immune system. years apart for anyone with which vaccine formulation is used.2-4 Immunization guidelines suggest that the theoretical specific high risk medical No trials have yet assessed the efficacy greater potency of PREVNAR over PNEUMOVAX may conditions (e.g.
    [Show full text]
  • Pneumococcal Vaccine Called PCV7, Or to Any Vaccine Spread from Person to Person Through Close Contact
    VACCINE INFORMATION STATEMENT Pneumococcal Conjugate Vaccine (PCV13) Many Vaccine Information Statements are available in Spanish and other languages. See www.immunize.org/vis Hojas de informacion sobre vacunas est&n What You Need to Know disponibles en espafiol y en muclios otros idiomas, Visite www.immunize.org/vis 1 Why get vaccinated? ] Some people should not get this vaccine Vaccination can protect both children and adults from pneumococcal disease. Anyone who has ever had a life-threatening allergic reaction to a dose of this vaccine, to an earlier Pneumococcal disease is caused by bacteria that can pneumococcal vaccine called PCV7, or to any vaccine spread from person to person through close contact. It containing diphtheria toxoid (for example, DTaP), can cause ear infections, and it can also lead to more should not get PC VI3. serious infections of the: • Lungs (pneumonia),' Anyone with a severe allergy to any component of • Blood (bacteremia), and PC VI3 should not get the vaccine. Tell your doctor if the • Covering of the brain and spinal cord (meningitis). person being vaccinated has any severe allergies. Pneumococcal pneumonia is most common among If the person scheduled for vaccination is not feeling adults. Pneumococcal meningitis can cause deafness and well, your healthcare provider might decide to brain damage, and it kills about 1 child in 10 who get it. reschedule the shot on another day. Anyone can get pneumococcal disease, but children under 2 years of age and adults 65 years and older, Risks of a vaccine reaction people with certain medical conditions, and cigarette With any medicine, including vaccines, there is a chance smokers are at the highest risk.
    [Show full text]
  • Adult Pneumococcal Vaccination Recommendations
    Adult Pneumococcal Vaccination Recommendations Background1,2 Streptococcus pneumoniae is a leading cause of invasive disease, including bacteremia, meningitis, and pneumonia in the United States. It is estimated to be responsible for 4 million episodes of illness, 445,000 hospitalizations, and 22,000 deaths per year. Incidence of invasive disease ranges from 3.8 cases per 100,000 persons among adults aged 18-34 years to 36.4 cases per 100,000 persons among adults aged ≥ 65 years. Patients with high-risk immunocompromising medical conditions, such as hematologic malignancies and human immunodeficiency virus, have up to a 20-fold increased risk for invasive pneumococcal disease. The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) currently recommends pneumococcal for all adults aged ≥ 65 years, as well as adults aged 19-64 years with immumocompromising conditions. Two pneumococcal vaccines are available, 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent polysaccharide vaccine (PCV13). The recommendations below outline the preferred formulations and vaccination schedules according to the ACIP guidelines. Pneumococcal Vaccination for Adults Aged ≥ 65 Years3,4 In 2010, ACIP recommended that all adults should be vaccinated with PPSV23 at age 65 years. In 2014, these recommendations were updated based on results from a randomized, placebo-controlled trial showing efficacy of PCV13 in preventing pneumonia in 85,000 adults aged ≥ 65 years. ACIP now recommends that both PCV13 and PPSV23 should be routinely administered to all adults aged ≥ 65 years. In addition, ACIP recently revised the recommended intervals for sequential use of PCV13 and PPSV23 in this patient population.
    [Show full text]
  • Pneumococcal Vaccination Recommendations
    D E I S L A O N H Pneumococcal Vaccination D R D H E T Recommendations P L A 1-4 COLLEGE OF R A Adults ≥19 Years PHARMACY T E M H DRUG INFORMATION F E N T O (Including updated recommendations for the use of PCV13 in Adults) SERVICES 401-874-9188 Healthy Adults ≥ 65 Pneumococcal Vaccination Previously vaccinated with Previously vaccinated with Naive or Unknown History PPSV23 at age ≥65 PPSV23 before age 65 ≥ 1 year after PPSV23 GIVE: PCV13 ≥ 1 year after PPSV23 GIVE: PCV13 if not previously given Wait ≥ 1 year* Wait ≥ 1 year* (and ≥ 5 years after PPSV23) GIVE: PPSV23† GIVE: PCV13 if not previously given GIVE: PPSV23† ADULTS ≥ 19 with UNDERLYING MEDICAL CONDITIONS (see chart on back) OR who SMOKE or live in a NURSING HOME Pneumococcal Vaccination Previously vaccinated with one Naive or Unknown History dose PPSV23 Vaccination is NOT indicated for healthy persons GIVE: PPSV23 19 - 64 years of age While PCV13 is FDA-approved for persons > 50 years, the Advisory At Age ≥65 At Age ≥65 Committee on Immune Practices GIVE: PCV13 ≥ 1 year after PPSV23 GIVE: PCV13 ≥ 1year after PPSV23 does not provide guidance for use THEN: PPSV23† ≥ 1 year* after THEN: PPSV23† ≥ 1 year* after in this population. PCV13 and ≥ 5 years after PPSV23 PCV13 and ≥ 5 years after PPSV23 ADULTS ≥ 19 with IMMUNE COMPROMISING CONDITIONS (see chart on back), OR ASPLENIA (including sickle cell anemia), CEREBROSPINAL FLUID LEAK, or COCHLEAR IMPLANT Pneumococcal Vaccination Previously vaccinated with one Previously vaccinated with Naive or Unknown History dose PPSV23 two doses of
    [Show full text]
  • Immunizers Guide to Flu and PPV Vaccinations
    2009-2010 Immunizers’ Question & Answer Guide to Medicare Coverage of Seasonal Influenza and Pneumococcal Vaccinations Steps to Promoting Wellness Adult Immunizations The issues involved in Medicare billing and administration can be complex and may vary state to state. For this reason, we recommend that you contact your local fiscal intermediary/AB MAC, carrier/AB MAC (Part B), or the Centers for Medicare & Medicaid Services’ Regional Office for more detailed information. Centers for Medicare & Medicaid Services Medicare Influenza and Pneumococcal Vaccination Benefits 2009-2010 Immunizer’s Q&A Guide to Medicare Coverage9/23/2009 Table of Contents A. Introduction ........................................................................................................................................... 4 Purpose ................................................................................................................................................ 4 2009-2010 Update on H1N1 ............................................................................................................... 4 Background of Medicare Pneumococcal and Seasonal Influenza Vaccination Benefits .................... 5 ACIP Guidelines .................................................................................................................................. 5 Summary of ACIP Guidelines ............................................................................................................. 6 Who Should Not Be Vaccinated ......................................................................................................
    [Show full text]
  • Immunization Recommendations for College Students
    OCTOBER 2018 ACHA Guidelines Immunization Recommendations for College Students mmunizations offer safe and effective protection from vaccine-preventable diseases and outbreaks. The United States is experi- encing re-emergence of these diseases, in part due to factors such as un-immunized and under-immunized persons and global travel. I The American College Health Association (ACHA) strongly supports the use of vaccines to protect the health of our individual students and our campus communities. In recognition of the vital role that vaccine coverage plays in community immunity (herd immunity), ACHA discourages use of nonmedical exemptions to required vaccines. This guidance is provided to facilitate implementation of a comprehensive institutional immunization policy. Best practices for institu- tions of higher education include the following Immunization Recommendations for College Students (IRCS), encouraging students who request nonmedical exemptions to required vaccines to be counseled by a health service clinician, and considering exclusion of un- immunized students from school during outbreaks of vaccine-preventable diseases. Institutions may also be subject to additional requirements for pre-matriculation vaccinations and the granting of exemptions by state law. The ACHA Vaccine-Preventable Diseases Advisory Committee updates this document in accordance with changing public health rec- ommendations. These guidelines follow Advisory Committee on Immunization Practices (ACIP) recommendations published by the U.S. Centers for Disease
    [Show full text]
  • Pneumococcal Vaccine Timing and PPSV23 at the Same Visit
    DO NOT administer PCV13 Pneumococcal Vaccine Timing and PPSV23 at the same visit. Age 65+ Years (no underlying conditions) Discuss Options 1 vs. 2 with Patient Option 1 – PPSV23 only PPSV 23 Pneumovax® 23 OR Option 2 – PCV13 + PPSV23 Consider PCV13 for persons who have not received it and have at least one of these conditions: • Consider regularly oering if resides in nursing home or other long-term care facility, or resides in or is traveling to settings with low rates of pediatric immunization with PCV. • Consider oering if in group A below (smoker, or chronic conditions). No history of PCV 13 1 year PPSV 23 pneumococcal vaccine Prevnar13® (8 weeks for groups B & C below) Pneumovax® 23 Received PPSV23 1 year PCV 13 1 year after PCV13 and PPSV 23 before age 65 Prevnar13® 5 years after prior dose of PPSV23 Pneumovax® 23 Received PPSV23 1 year PCV 13 at age 65 or older Prevnar13® • If PCV13 was given before age 65 years, no additional PCV13 is needed. Age 19+ Years with Underlying Conditions • Prior doses count towards doses recommended below and do not need to be repeated. • If PPSV23 given previously – wait one year before giving PCV13 – for group B and <65 years of age, wait at least ve years before giving a second dose of PPSV23. • If doses below completed before age 65 years, oer one additional dose of PPSV23 on or after the 65th birthday and at least 5 years after most recent dose. No more than two doses of PPSV23 recommended before 65th birthday and one dose thereafter.
    [Show full text]